Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma
Open Access
- 1 January 2013
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 19 (24), 3872-3882
- https://doi.org/10.3748/wjg.v19.i24.3872
Abstract
AIM: To compare radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) with RFA monotherapy in hepatocellular carcinoma (HCC). METHODS: We searched PubMed, Medline, Embase and Chinese databases (CBMdisc and Wanfang data) for randomized controlled trails comparing RFA plus TACE and RFA alone for treatment of HCC from January 2000 to December 2012. The overall survival rate, recurrence- free survival rate, tumor progression rate, and safety were analyzed and compared. The analysis was conducted on dichotomous outcomes and the standard meta-analytical techniques were used. Pooled odds ratios (ORs) with 95% CIs were calculated using either the fixed-effects or random-effects model. For each meta-analysis, the chi(2) and I-2 tests were first calculated to assess the heterogeneity of the included trials. For P < 0.05 and I-2 > 50%, the assumption of homogeneity was deemed invalid, and the random-effects model was used; otherwise, data were assessed using the fixed-effects model. All statistical analysis was conducted using Review manager (version 4.2.2.) from the Cochrane collaboration. RESULTS: Eight randomized controlled trials were identified as eligible for inclusion in this analysis and included 598 patients with 306 treated with RFA plus TACE and 292 with RFA alone. Our data analysis indicated that RFA plus TACE was associated a significantly higher overall survival rate (OR1-year = 2.96, 95% CI: 1.84-7.74, P < 0.001; OR2-year = 3.72, 95% CI: 1.24-11.16, P = 0.02; OR3-year = 2.65, 95% CI: 1.81-3.86, P < 0.001) and recurrence-free survival rate (OR3-year = 3.00, 95% CI: 1.75-5.13, P < 0.001; OR5-year = 2.26, 95% CI: 1.43-3.57, P = 0.0004) vs that of RFA alone. The tumor progression rate in patients treated with RFA alone was higher than that of RFA plus TACE (OR = 0.60, 95% CI: 0.42-0.88, P = 0.008) and there was no significant difference on major complications between two different kinds of treatment (OR = 1.20, 95% CI: 0.31-4.62, P = 0.79). Additionally, the meta-analysis data of subgroups revealed that the survival rate was significantly higher in patients with intermediate-and large-size HCC underwent RFA plus TACE than in those underwent RFA monotherapy; however, there was no significant difference between RFA plus TACE and RFA on survival rate for small HCC. CONCLUSION: The combination of RFA with TACE has advantages in improving overall survival rate, and provides better prognosis for patients with intermediate-and large-size HCC. (C) 2013 Baishideng. All rights reserved.Keywords
This publication has 30 references indexed in Scilit:
- CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvementEuropean Journal of Radiology, 2012
- Combination of Radiofrequency Ablation with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-AnalysisDigestive Diseases and Sciences, 2012
- Small Hepatocellular Carcinoma: Is Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization More Effective than Radiofrequency Ablation Alone for Treatment?Radiology, 2009
- Transarterial Injection of 131I-Lipiodol, Compared with Chemoembolization, in the Treatment of Unresectable Hepatocellular CancerJournal of Nuclear Medicine, 2009
- Chemoembolization Combined With Radiofrequency Ablation for Patients With Hepatocellular Carcinoma Larger Than 3 cmJama-Journal Of The American Medical Association, 2008
- Intraoperative radiofrequency thermal ablation combined with portal vein infusion chemotherapy and transarterial chemoembolization for unresectable HCC.2005
- Percutaneous radiofrequency ablation for hepatocellular carcinomaCancer, 2005
- [Percutaneous radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma].2002
- Estimating the world cancer burden: Globocan 2000International Journal of Cancer, 2001
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986